Following these transactions, Gilson will own 9,582 shares of Arcellx common stock. The sales included broker-assisted transactions to cover tax liabilities related to the vesting of restricted stock units. The company maintains a strong financial position with a current ratio of 4.29, which indicates the availability of sufficient liquidity to meet its short-term obligations. For deeper insights into Arcellx's financial health and additional metrics, investors can access the comprehensive Pro Research report available at InvestingPro. The company maintains a strong financial position with a current ratio of 4.29, which indicates the availability of sufficient liquidity to meet its short-term obligations. For deeper insights into Arcellx's financial health and additional metrics, investors can access the comprehensive Pro Research report available at InvestingPro.
Additionally, on January 8, 2025, Gilson conducted another sale of shares totaling $654,065, at prices ranging from $73.6929 to $75.5283. These transactions were part of a Rule 10b5-1 trading plan, which was originally established on December 18, 2023, and later amended on March 27, 2024. Despite the recent price movements, analysts are maintaining price targets ranging from $104 to $134 per share. .
Following these transactions, Gilson will own 9,582 shares of Arcellx common stock. The sales included broker-assisted transactions to cover tax liabilities related to the vesting of restricted stock units.
In other recent news, Arcellx Inc. A series of positive developments, with several companies maintaining their buy ratings and increasing their price targets. Stifel and TD Cowen highlighted the potential of Arcellx's candidate, anito-cel, in the multiple myeloma market, with Stifel reiterating a Buy rating and $122.00 price target. BofA Securities raised its price target to $112 from $100 previously, while maintaining a buy rating, following the announcement of iMMagine-1 interim pivotal data for anito-cel. Truist Securities echoed that sentiment, raising its price target to $136 from $87 previously, citing Arcellx's strong financial position and Anito-cel's promising data.
Piper Sandler maintained an Overweight rating and increased its price target to $115 following Arcellx's third-quarter 2024 earnings report. Both companies noted significant results from clinical studies of Anitocell for the treatment of relapsed or refractory multiple myeloma, where a Phase 1 study showed an average of ​Progression-free survival of 30.2 months, the phase 2 iMMagine-1 study showed an overall response of 95%. an average.
Arcellx's manufacturing capabilities for Anito-cel have also been praised, which could give it a significant advantage in the cancer therapeutics market. These latest developments were driven by Arcellx's progress and the upcoming release of full data from anito-cel's iMMagine-1 study.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
